Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice

被引:146
|
作者
Haberer, Jessica E. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
adherence; preexposure prophylaxis; HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; SELF-REPORT; RISK; MEN; SEX; PREVENTION; INFECTION; TENOFOVIR; INTERVENTIONS;
D O I
10.1097/COH.0000000000000220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewThe review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention.Recent findingsPrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies.SummaryPrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [1] Implementing HIV PrEP in Routine Practice
    Sell, Jarrett
    AMERICAN FAMILY PHYSICIAN, 2023, 108 (03) : 227 - 228
  • [2] Real-Time Monitoring and Point-of-Care Testing: A Review of the Current Landscape of PrEP Adherence Monitoring
    Hannaford, Alisse
    Arens, Yotam
    Koenig, Helen
    PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 259 - 269
  • [3] Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV
    Yun, Ke
    Xu, Jun-jie
    Zhang, Jing
    Li, Jia-ming
    Hu, Qing-hai
    Chu, Zhen-xing
    Jiang, Yong-jun
    Geng, Wen-qing
    Shang, Hong
    Wang, Ning
    SEXUALLY TRANSMITTED INFECTIONS, 2018, 94 (03) : 163 - 168
  • [4] The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082
    Beauchamp, Geetha
    Hosek, Sybil
    Donnell, Deborah
    Chan, Kwun C. G.
    Anderson, Peter L.
    Dye, Bonnie J.
    Mgodi, Nyaradzo
    Bekker, Linda-Gail
    Delany-Moretlwe, Sinead
    Celum, Connie
    AIDS AND BEHAVIOR, 2024, 28 (05) : 1512 - 1521
  • [5] PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials
    Dimitrov, Dobromir T.
    Masse, Benoit R.
    Donnell, Deborah
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (04) : 444 - 451
  • [6] Absorbing Markov chain model of PrEP drug adherence to estimate adherence decay rate and probability distribution in clinical trials
    Dale, Renee
    He, Hongyu
    Chen, Yingqing
    JOURNAL OF THEORETICAL BIOLOGY, 2025, 604
  • [7] PrEP implementation: moving from trials to policy and practice
    Caceres, Carlos F.
    O'Reilly, Kevin R.
    Mayer, Kenneth H.
    Baggaley, Rachel
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18 : 1 - 4
  • [8] The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USA
    Elion, Richard
    Coleman, Megan
    CURRENT OPINION IN HIV AND AIDS, 2016, 11 (01) : 67 - 73
  • [9] Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials
    Agot, Kawango
    Taylor, Douglas
    Corneli, Amy L.
    Wang, Meng
    Ambia, Julie
    Kashuba, Angela D. M.
    Parker, Caleb
    Lemons, Ansley
    Malahleha, Mookho
    Lombaard, Johan
    Van Damme, Lut
    AIDS AND BEHAVIOR, 2015, 19 (05) : 743 - 751
  • [10] Acceptability in microbicide and PrEP trials: current status and a reconceptualization
    Mensch, Barbara S.
    van der Straten, Ariane
    Katzen, Lauren L.
    CURRENT OPINION IN HIV AND AIDS, 2012, 7 (06) : 534 - 541